SG/CALL/BRISTOL-MYERS SQUIBB/62/0.1/21.06.24 | Delayed Deutsche Boerse AG 10:16:42 11/06/2024 BST | ||
| 0.001 EUR | 0.00% |
|
| 6 months | -98.36% | ||
| Current year | -98.44% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 11/06/24 | 0.001 | 0.00% |
| 10/06/24 | 0.001 | 0.00% |
| 07/06/24 | 0.001 | 0.00% |
| 06/06/24 | 0.001 | 0.00% |
| 05/06/24 | 0.001 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 11, 2024 at 10:16 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SU2KFX |
| ISIN | DE000SU2KFX9 |
| Date issued | 21/11/2023 |
| Strike | 62 $ |
| Maturity | 21/06/2024 (10 Days) |
| Parity | 10 : 1 |
| Emission price | 0.061 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.098 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.019 € |
| Spread % | 95.00% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
42.57
USD
Average target price
53.19
USD
Spread / Average Target
+24.96%
- Stock Market
- Warrants
- Warrant
